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To unravel the molecular mechanisms mediating
the effects of androgens on spermatogenesis, tes-
ticular gene expression was compared inmice with
Sertoli cell-selective androgen receptor knockout
(SCARKO) and littermate controls on postnatal d
10. Microarray analysis identified 692 genes with
significant differences in expression. Of these, 28
appeared to be down-regulated and 12 up-regu-
lated at least 2-fold in SCARKOs compared with
controls. For nine of the more than 2-fold down-
regulated genes, androgen regulation was con-
firmed by treatment of wild-type mice with an an-
tiandrogen (flutamide). Some of them were
previously described to be androgen regulated or
essential for spermatogenesis. Serine-type pro-
tease inhibitors were markedly overrepresented in
this down-regulated subgroup. A time study (d
8–20), followed by cluster analysis, allowed identi-
fication of distinct expression patterns of differen-
tially expressed genes. Three genes with a pattern
closely resembling that of Pem, a prototypical an-
drogen-regulated gene expressed in Sertoli cells,
were selected for confirmation by quantitative RT-
PCR and additional analysis. The data confirm that
the SCARKO model allows identification of novel
androgen-regulated genes in the testis. Moreover,
they suggest that protease inhibitors and other
proteins related to tubular restructuring and cell
junction dynamics may be controlled in part by
androgens. (Molecular Endocrinology 20: 321–334,
2006)
DESPITE THE OVERWHELMING evidence that an-drogens play a key role in the control of spermat-
ogenesis (1–6), the cellular and molecular mechanisms
underlying this control remain poorly understood.
Germ cells, peritubular myoid cells, and Sertoli cells
(SC) have been mentioned as potential androgen tar-
get cells, but their relative contributions to the control
of spermatogenesis remain unclear. Germ cells prob-
ably do not express the classical androgen receptor
(AR) (7), and they certainly do not need it for normal
development (8, 9). However, alternative mechanisms
of androgen action, for instance, via conversion into
estrogens (10) or via nongenomic pathways (11, 12),
cannot be excluded. Peritubular myoid cells are lo-
cated in the vicinity of spermatogonia. They do ex-
press the AR (13); moreover, they depend on andro-
gens for their normal development (14). Furthermore,
androgen-modulated interactions between peritubular
cells and SC have been described (15, 16). SC display
intimate interactions with germ cells at all stages of
spermatogenesis (17, 18) and express the AR in a
stage-dependent manner (13). Therefore, they are
usually considered to be the most likely mediators of
androgen action on spermatogenesis.
Because attempts to use isolated and cultured SC
to study the molecular mechanisms of androgen ac-
tion in the control of spermatogenesis have been
largely unsuccessful (19, 20), we and others have re-
cently developed in vivo models in which the AR gene
is selectively inactivated in SC during embryonic de-
velopment (from d 15 post coitum), more than 1 wk
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before immunoexpression becomes evident (postnatal
d 3–5) (21–23). In our laboratory, knockout of the AR
gene was achieved by crossing mice with a floxed
exon 2 of the AR with mice expressing Cre under
control of the anti-Mullerian hormone promoter (AMH-
Cre) (24). These mice (SCARKO mice) have normally
descended testes, virtually absent levels of Pem (a
prototypical gene expressed in SC under control of
androgens), normal AR expression in Leydig and peri-
tubular cells, and normal circulating levels of andro-
gens and LH. Spermatogenesis, however, is arrested
in meiosis.
In the present study we have used the GeneChip
Mouse Expression Array 430a 2.0 to identify genes
that are differentially expressed in the testis of
SCARKO and control (AMH-Cre) littermates on d 10, a
time point at which differences in AR expression have
not yet resulted in noticeable differences in cellular
composition of the testis. A subset of 692 genes,
including the Pem gene, was differentially expressed
in a statistically significant manner. Among these dif-
ferentially expressed genes, serine-type protease in-
hibitors were clearly overrepresented. Analysis of tes-
ticular gene expression in SCARKO and control mice
between d 8 and 20 allowed cluster analysis and iden-
tification of some typical gene expression patterns of
androgen-regulated genes. A subset of genes with an
expression pattern resembling that of Pem was se-
lected for additional analysis. Furthermore, functional
analysis of the data suggested that androgen action in
SC may affect tubular remodeling and junction
dynamics.
RESULTS
The microarray datasets generated in this study are
available through National Center for Biotechnology
Information via the Gene Expression Omnibus (GEO)
data repository (http://www.ncbi.nih.gov/geo/), GEO
accession nos. GSE2259 and GSE2260.
Identification of Differentially Expressed
Transcripts in Control vs. SCARKO Testes
on d 10
To avoid confounding effects of differences in testic-
ular cell composition related to the meiotic arrest oc-
curring in SCARKO mice, gene expression patterns in
SCARKO and control littermates were compared on d
10. At this age, testicular weights were identical in
SCARKO and control mice [mean  SEM, 4.55  0.18
mg (n 25) and 4.58 0.16 mg (n 17), respectively].
Moreover, tubular and germ cell complements were
still comparable, as confirmed by hematoxylin/eosin
staining and immunostaining for Dazl, a germ cell-
specific RNA-binding protein. Nonetheless, on d 10,
the AR was clearly immunoexpressed in SC nuclei of
control mice, whereas it was completely absent in SC
of SCARKO mice (Fig. 1). As expected, AR staining in
interstitial and peritubular myoid cells was comparable
for SCARKO and control mice (21).
Statistical analysis of microarray data from five in-
dependent samples of 10-d-old SCARKO and control
mice (see Materials and Methods) generated a list of
848 differentially expressed transcripts corresponding
Fig. 1. Hematoxylin/Eosin (H&E) Staining and Immunoexpression Profiles for AR and Dazl in Testes of 10-d-Old Control and
SCARKO Mice
H&E and Dazl staining show that testicular morphology and germ cell complement are still similar in control and SCARKO testes
on d 10. Immunostaining of the AR is observed in SC nuclei of control mice (arrows) but is absent in SC nuclei of SCARKO mice.
Scale bar, 50 m.
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to 692 genes after correction for the redundancy of
oligonucleotide probes (supplemental Table 1, pub-
lished on The Endocrine Society’s Journals Online
web site at http://mend.endojournals.org). Of these
genes, 296were expressed at a higher level in SCARKOs
compared with controls (referred to as up-regulated in
SCARKOs) and 396 were expressed at a lower level in
SCARKOs compared with controls (referred to as down-
regulated in SCARKOs). Forty of the identified genes
showed a difference in expression level of at least 2-fold.
The majority of the latter genes (n  28) displayed
lower expression levels in SCARKOs (strongly down-
regulated) compared with controls (Table 2).
Using Onto-Express software (25), the list of 396
genes that were down-regulated in SCARKOs re-
flected a significant (P  0.01) overrepresentation of
genes related to MAPK activity (n 4) and serine-type
endopeptidase inhibitor activity (n  6). Interestingly,
most of these serine-type endopeptidase inhibitors
[Eppin, Serpina3N, Serpina12, Pcskn1n, and protein C
inhibitor (PCI)] were down-regulated more than 2-fold
(Table 2). For the 296 genes that appeared up-regu-
lated in SCARKOs, overrepresentation was observed
for genes related to IGF binding (n  5), Ca2 binding
(n  16), Ca2-dependent phospholipid binding (n 
5), regulation of cell cycling (n  12) and cell growth
(n 8), cell adhesion (n 13), and signal transduction
(n  43).
Confirmation of Androgen Regulation and
Tubular Localization for a Selection of Down-
Regulated Genes
To clarify the contribution of androgens to the differ-
ences in testicular gene expression identified by the
microarray experiments, 7-d-old wild-type mice were
treated for 3 or 5 d with the antiandrogen flutamide
(Flut) or with testosterone proprionate (TP), and the
expressions of nine of the strongly down-regulated
genes were measured by quantitative RT-PCR (Table
3). The selected genes comprised the four genes most
strongly down-regulated in SCARKOs (Pem, Eppin,
Galgt1, and DRD4), a testis-specific X-linked gene
(Tsx), a gene encoding an enzyme involved in lipid and
glucose metabolism (Gpd1), and genes encoding a
microtubular component (Tubb3), a serine protease
inhibitor (PCI), and a tumor protein (Tpd52l1). After 3 d
of treatment with Flut (d 10), the expression of all
studied genes tended to be decreased, but a signifi-
cant decrease was observed only for Pem, Eppin,
Drd4, and Gpd1. After 5 d of Flut (d 12), the expres-
sions of all studied genes were significantly de-
creased. With the exception of Galgt1, genes that
were most strongly down-regulated in SCARKOs
tended to be more sensitive to inhibition by Flut. In-
terestingly, on d 10, TP still increased the expression
of three of the studied genes, whereas on d 12, stim-
ulatory effects were absent, and inhibitory effects were
observed for five of the selected genes, suggesting
that, already at that age, intratesticular androgen lev-
els may be decreased by treatment with TP.
Enzymatic digestion, followed by quantitative RT-
PCR, were used to study the interstitial or tubular
localization of the same subset of selected genes in
10-d-old wild-type mice. Pem and SCP3 were used as
markers of tubular localization (for SC and spermato-
cytes, respectively), and P450c17 (Leydig cells) was
used as a marker for interstitial localization. As shown
in Table 4, the data point to a predominantly tubular
localization for all selected genes.
Expression Patterns of Transcripts Differentially
Expressed on d 10 in SCARKO and Control Mice
during Prepubertal Development
To analyze the relationship of the differentially ex-
pressed genes, identified above, to the initiation of
spermatogenesis and the development of the testis,
gene expression was assessed in testis samples de-
rived from SCARKO and control littermates at five
different ages (d 8, 10, 12, 16, and 20).
The physiological relevance of the resulting data
was supported by the expression pattern displayed by
a number of typical meiotic marker genes (Fig. 2).
Dmc1, for instance, and SCP3, which are known to be
expressed during early stages of meiosis, showed a
marked increase in expression from d 12 onward and
displayed similar expression profiles in control and
SCARKO testes. In contrast, genes such as heat
Table 1. Oligonucleotide Primers Used for Quantitative RT-PCR










Accession number of gene sequences used for primer design can be found in Table 2.
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shock protein 70-2 (Hsp70-2) and proacrosin-binding
protein (Acrbp) displayed their steepest increase in
expression later in meiosis (from d 16 on) and rose
more markedly in controls than in SCARKOs, a finding
compatible with the previously described progressive
disruption of meiosis in SCARKO testes.
Cluster analysis of the transcripts found to be dif-
ferentially expressed on d 10 resulted in the identifi-
cation of 14 clusters encompassing 796 transcripts.
Clusters containing at least 30 genes are shown in Fig.
3A, and the detailed data can be consulted in supple-
mental Table 2. The vast majority of the transcripts
that showed a difference in expression level of at least
2-fold when comparing SCARKO and controls were
found in clusters 3, 4, and 5. Clusters 1, 2, and 6
grouped genes with more limited differences in ex-
Table 2. Genes with a More than 2-Fold Difference in Expression Level between SCARKO and Control (Ctrl)
Gene Name (Gene symbol) Accession No. Fold Difference
A. Genes with Lower Expression Level in SCARKO than in Control Testes Ctrl/SCARKO
Placentae and embryos oncofetal gene (Pem) BM210473 17.55
Serine protease inhibitor, with Kunitz and WAP domains 1 (Spinlw1)/Eppin NM_029325 8.01
-1,4-Acetylgalactosaminyltransferase (Galgt1) U18975 7.07
Dopamine receptor 4 (Drd4) NM_007878 5.61
Serine (or cysteine) proteinase inhibitor, clade A, member 3N (Serpina3N) NM_009252 5.49
Chaperonin subunit 3 (Cct3)/Matricin L20509 5.09
Testis specific X-linked gene (Tsx) NM_009440 5.01
Low-density lipoprotein receptor-related protein 4 (Lrp4)/Corin NM_016869 3.92
Recombinant antineuramidase single chain Ig VH and VL domains (LOC56304) NM_019633 3.53
Glycerol-3-phosphate dehydrogenase 1 (soluble) (Gpd1) BC019391 3.42
Mcf.2 transforming sequence (Mcf2)/Diffuse B-cell lymphoma oncogene (Dbl) NM_133197 2.83
Serine (or cysteine) proteinase inhibitor, clade A, member 12 (Serpina12) AK014346 2.60
Expressed sequence AW125753 (AW125753) BC002154 2.58
START domain containing 10 (Stard10)/Phosphatidylcholine transfer protein-like (PCTP-L) NM_019990 2.56
RIKEN cDNA 1700112P19 gene (1700112P19Rik) NM_026459 2.50
Ecotropic viral integration site 1 (Evi1) NM_007963 2.46
Solute carrier family 22 (organic cation transporter), member 4 (Slc22a4) BC010590 2.45
RIKEN cDNA 1500031H04 (1500031H04Rik) BC017627 2.38
Proprotein convertase substilisin/kexin type 1 inhibitor (Pcsk1n)/Granin-like neuroendocrine
peptide precursor
AF181560 2.36
RIKEN cDNA 2300002F06 (2300002F06Rik) BC024546 2.35
Tubulin, 3 (Tubb3) NM_023279 2.34
Serine (or cysteine) proteinase inhibitor, clade A, member 5 (Serpina5)/Protein C inhibitor
(PCI)
NM_172953 2.33
Cysteine dioxygenase 1, cytosolic (Cdo1) NM_033037 2.30
Calsyntenin 1 (Clstn1) BG065300 2.25
Tumor protein D52-like (Tpd52l1) NM_009413 2.19
N-acetylglutamate synthase (Nags) AF462069 2.15
Butyrophilin related 1 (Butr1) NM_138678 2.13
Carbonic anhydrase 5b, mitochondrial (Car5b) NM_019513 2.09
B. Genes with Higher Expression Level in SCARKO than in Control Testes SCARKO/Ctrl
Z-DNA binding protein 1 (ZBP1)/DLM-1 NM_021394 4.28
Lectin, galactose binding, soluble 7 (Lgals7)/Galectin-7 AF038562 4.01
Fatty acid binding protein 7, brain (Fabp7) NM_021272 3.94
Regucalcin (Rgn)/Senescence marker protein 30 (SMP30) NM_009060 3.46
— S69212 3.42
RIKEN cDNA 1810010M01 (1810010M01Rik) BF581690 2.79
Desmocollin 2 (Dsc2) BC004663 2.44
Mus musculus, clone IMAGE:4188338, mRNA, partial cds/epiplakin 1 (Eppk1) BC026387 2.25
Desmoglein 2 (Dsg2) BG092030 2.18
Myeloblastosis oncogene (Myb) NM_033597 2.18
6-Pyruvoyl-tetrahydropterin synthase/dimerization cofactor of hepatocyte nuclear factor 1 
(TCF1/Pcbd)
NM_025273 2.02
Nectin-like 1 (Necl1)/Mus musculus Ig superfamily, member 4B (Igsf4b) NM_053199 2.01
Differentially expressed genes with an average fold difference of 2 or more across the pairwise comparison of mRNA expression
in testes of 10-d-old control vs. SCARKO mice. Statistical significance was confirmed by three different statistical tests (see
Materials and Methods). For genes represented by more than one transcript in this list, only the transcript with the highest fold
difference was retained.
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pression level on d 10. Cluster 1 genes were charac-
terized by a progressive decline in expression from d
8 to 20. The decline was more pronounced in controls
than in SCARKOs. Cluster 2 genes displayed a marked
decline in expression in control testes from d 12 on-
ward, whereas expression in SCARKOs remained rel-
atively stable. Cluster 6 genes were characterized by a
late-onset (d 16) increase in expression that was more
pronounced in controls than in SCARKOs.
Cluster 5 contained transcripts with a decreasing
expression pattern from d 8–20 and with higher ex-
pression levels in SCARKOs than in controls. The time
course of the most representative transcript (minimal
distance between expression profile and cluster cen-
ter) for this cluster (RIKEN cDNA 6530411B15) is illus-
trated in Fig. 4. Five of the 12 transcripts with a more
than 2-fold higher expression level in SCARKO testes
(Table 2 and supplemental Table 2) were found in this
cluster.
Eight and 12 of the genes that had a more than
2-fold lower expression level in SCARKO testes than in
control testes (29% and 43% of this entire subgroup)
were found in clusters 3 and 4, respectively (Table 2
and supplemental Table 2). Prototypical genes of clus-
ters 3 (phosphatidylinositol 4-kinase type 2) and 4
(N-acetylglutamate synthase) are shown in Fig. 4. The
expression of the transcripts found in cluster 3 in-
creased over the study period, more so in controls
than in SCARKOs (Fig. 4). Transcripts in cluster 4 were
Fig. 2. Representative Expression Profiles (d 8–20) of Early
(Dmc1 and SCP3) and Late (Acrbp and Hsp70-2) Meiotic
Marker Genes
Microarray signal values (RMA normalized) were normal-
ized to the highest signal value observed for the studied gene
in SCARKO or control testes, arbitrarily set at 100. The re-
sulting values are designated the relative signal intensity for
the studied gene at the indicated time points.
Table 4. Gene Expression in Interstitial and Tubular
Fractions in Testes at d 10
Interstitial Compartment Tubular Compartment
P450c17 1335  202 4  2
SCP3 20  3 128  38
Pem 8  2 85  27
Eppin 81  13 645  91
Galgt1 21  4 339  86
Drd4 9  0 21  4
Tsx 69  20 367  129
Gpd1 9  1 51  6
Tubb3 277  80 3579  1553
PCI 1548  343 8284  2189
Tpd52l1 348  76 2001  451
Interstitial and tubular fractions were isolated by enzymatic
digestion of testes from 10-d-old mice and gene expression
levels were determined by quantitative RT-PCR. Results are
expressed as the number of mRNA copies per 108 copies of
18S rRNA, and values shown are means  SEM from three
independent experiments. Pem and SCP3 are markers for the
tubular compartment (SC and germ cells, respectively).
P450c17 is a marker for the interstitial compartment (Leydig
cells).
Table 3. Effect of (Anti)-Androgen Treatment on Testicular Gene Expression
Treatment
d 10 d 12
Control Flut TP Control Flut TP
Pem 100  26 11  2a 432  50a 100  18 2  1a 102  22
Eppin 100  9 35  4a 143  15a 100  24 19  4a 57  15
Galgt1 100  30 81  16 226  20a 100  6 53  7a 102  9
Drd4 100  10 12  2a 102  13 100  30 23  9a 36  14a
Tsx 100  15 84  13 129  10 100  17 15  3a 76  17
Gpd1 100  11 43  7a 101  9 100  21 19  5a 35  9a
Tubb3 100  10 83  8 89  8 100  10 46  9a 64  6a
PCI 100  8 77  11 81  7 100  10 56  5a 77  6a
Tpd52l1 100  23 72  8 79  5 100  4 54  4a 83  5a
Seven-day-old male C57BL/6@Rj mice were treated for 3 or 5 d with TP (50 g/animal/d), Flut (50 g/animal/d), or vehicle
(Control). At d 10 or 12, mice were killed and testes were removed. Luciferase mRNA was added to the testis samples as an
external standard. RNA was extracted and cDNA was prepared as described in Materials and Methods. Each treatment group
consisted of five animals. Results are expressed as the number of mRNA copies per 108 copies of luciferase mRNA, and values
shown are means  SEM from three independent experiments.
a P  0.05, in comparison with respective control group.
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characterized by a limited increase in the SCARKO
testes, but a marked early increase in controls (up to d
12), followed by a slower decline (Fig. 4). Several of the
genes with the largest decrease in expression level in
SCARKO compared with controls (Pem, Eppin, Drd4,
and Gpd1; Table 2) were found in cluster 4.
Fig. 3. Expression Patterns of Transcripts, Differentially Expressed on d 10 in SCARKO and Control Mice, between d 8 and d 20
A, Adaptive quality-based clustering (AQBC) of transcripts differentially expressed on d 10. Cluster analysis was used to identify
subsets of transcripts with a similar expression pattern. Fourteen clusters were identified, containing 796 transcripts in total. Only
clusters containing at least 30 transcripts are shown. For each cluster, the representative expression profile is represented in bold.
B, Left, Hierarchical clustering of all transcripts present in cluster 4. Columns indicate different genotypes (control and SCARKO)
and ages (d 8–20), and rows show the expression patterns for individual genes. Expression levels are visualized using a color code
in which expression decreases from dark red (highest expression level) to dark green (lowest expression level). Genes are grouped
based on the resemblance of their expression pattern to that of neighboring genes. The panel on the right gives a detailed view
of the transcripts with an expression pattern most strongly resembling that of Pem. C, Expression pattern of Pem. Relative signal
intensities were calculated as explained in Fig. 2.
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Because Pem was previously shown to be directly
regulated by androgens in SC, and the main aim of our
study was to identify additional androgen-regulated
genes in SC, we specifically searched for genes whose
expression pattern most strongly resembled that of
Pem (Fig. 3C). To this end, pairwise Euclidian dis-
tances between all profiles in cluster 4 were calcu-
lated and visualized using hierarchical clustering as
implemented in Expression Profiler (EPCLUST) (26).
Figure 3B shows that the expression profiles of Ep-
pin, Drd4, and Gpd1 most strongly resemble that of
Pem. Therefore, these genes were retained for ad-
ditional analysis. Mtap7 was represented on the array
by several transcripts, and because not all of them
shared the same expression pattern, this gene was not
included.
Genes with an Expression Pattern Resembling
that of Pem
The expressions of Pem, Eppin, Drd4, and Gpd1 were
studied from d 2–20 using quantitative RT-PCR. The
data summarized in Fig. 5 confirm a similar expression
pattern as a function of age for the four genes studied
and noticeably higher expression in controls com-
pared with SCARKOs at all ages. This difference in
expression remained evident on d 50 (data not shown).
In contrast to the expression pattern of these genes as
studied by microarray analysis (illustrated for Pem in
Fig. 3C) the expression pattern studied by quantitative
RT-PCR did not show a decline after d 12. This may be
explained by the fact that the quantitative RT-PCR
data are normalized to exogenously added luciferase
mRNA to obtain an estimate of the absolute number
of transcripts per testis. The absence of such a
normalization for the microarray data means that
transcripts in a particular cell type (for instance, SC)
will be diluted in the total amount of transcripts
when another cell population (in this case, the germ
cells) is making up an increasing proportion of the
total testicular volume.
Effects of SC-Selective AR Inactivation on
Genes Related to Tubular Remodeling and
Junction Dynamics
Given the finding from the original d 10 study that
transcripts encoding serine protease inhibitors and
cell adhesion molecules are overrepresented in the list
of genes differentially expressed in SCARKO and con-
trol testes, we explored whether androgen action in
SCmight play a role in tubular remodeling and junction
dynamics. Time patterns were analyzed for transcripts
differentially expressed on d 10 and encoding poten-
tially relevant proteins, such as proteases and pro-
tease inhibitors, cytoskeletal elements, extracellular
matrix molecules, and cell adhesion molecules. The
data summarized in Fig. 6 illustrate that differentially
expressed transcripts were found for each of these
categories of molecules, and that for all transcripts,
differential expression was observed at several time
points. For many genes, including Eppin, PCI, tissue-
type plasminogen activator (tPA), tubulin 3 (Tubb3),
procollagen type IV 6 (Col4a6), brevican (Bcan), clau-
din 11 (Cldn11), and desmocollin (Dsc2), differential
expression was already evident on d 8. For other
genes, such as actinin 3 (Actn3), scinderin (Scin),
thrombospondin 1 (Thbs1), and embigin (Emb), differ-
ential expression was absent or marginal on d 8, but
increased toward d 12. As explained above, the de-
cline in relative signal intensity observed in control
testes after d 12 may be due at least in part to the
increase in the relative proportion of germ cells in the
testis.
DISCUSSION
Recently developed transgenic models in which the AR
is selectively inactivated in SC support the contention
that SC play a pivotal role in the control of spermatogen-
esis by androgens (21–23). In this study we used the
Fig. 4. Expression Patterns of the Most Representative Transcripts of Clusters 5, 3, and 4 in the AQBC Clustering of the
Differentially Expressed Genes
RIKEN cDNA 6530411B15 gene (6530411B15Rik), phosphatidylinositol 4-kinase type 2  (Pi4k2b), and N-acetylglutamate
synthase (Nags) represent clusters 5, 3, and 4, respectively. Relative signal intensities were calculated as explained in Fig. 2.
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combination of such a model, the SCARKO mouse, and
microarray technology to analyze the molecular conse-
quences of selective absence of androgen action in SC
at the onset of spermatogenesis.
SCARKO mice develop spermatogenic arrest in
meiosis. Accordingly, to avoid confounding effects
due to the marked differences in tissue composition
once spermatogenesis proceeds beyond the sper-
matocyte stage, we selected d 10 as the main time
point to search for genes differentially expressed in
SCARKO and control testes. Earlier experiments on
the temporal mRNA expression of Pem suggested a
marked increase between d 7 and 9, reflecting the
onset of androgen action in SC (27). Moreover, the
present data show that 1) there are no differences in
testis weight between SCARKO testes and controls on
d 10; 2) apart from the absence of AR expression in SC
from SCARKO testes, the morphology of the testes is
comparable in SCARKO and control mice; and 3) the
expression of typical meiotic genes (Dmc1, SCP3,
Hsp70-2, Acrbp, etc.) is identical in d 10 SCARKO and
control testes.
Microarray analysis identified a subset of 692 genes
differentially expressed in SCARKO and control testes.
Of these genes, 396 were apparently down-regulated
in SCARKOs, and 296 were up-regulated. Although
the list covered a variety of functions, analysis using
Onto-express software revealed overrepresentation of
some potentially important genes/functions, including
genes encoding serine-type protease inhibitors
(down-regulated in SCARKOs) and genes related to
cell cycling, cell growth, cell-cell adherence, and sig-
nal transduction (up-regulated in SCARKOs). When
the list was limited to genes with an at least 2-fold
difference in expression level between SCARKOs and
controls, 28 down-regulated and 12 up-regulated
genes were retained, with genes encoding serine-type
endopeptidase inhibitors prominently present in the
subset of genes down-regulated in SCARKOs.
The detailed mechanisms responsible for the differ-
ential expression of individual genes in SCARKOs and
controls require further investigation. Because the pri-
mary difference between SCARKO and control testes,
however, resides in the absence or presence of a
functional AR in SC, genes that are down-regulated in
SCARKOs may reasonably be expected to depend on
androgen action in SC for their physiological expres-
sion, whereas genes that are up-regulated in SCAR-
KOs may be repressed by androgen action. Physio-
logically relevant levels of androgens are present in the
testis and the circulation on d 10 (28–32). Moreover,
the two genes showing the most pronounced differ-
ence in expression in the present experiments, Pem
and Eppin, have both previously been identified as
Fig. 5. mRNA Levels of Placentae and Embryos Oncofetal Gene (Pem), Dopamine Receptor 4 (Drd4), Serine Protease Inhibitor
with Kunitz and WAP Domains 1 (Eppin), and Glycerol-3-Phosphate Dehydrogenase 1 (Gpd1) in Control and SCARKO Testes
from d 2–20, as Determined by Quantitative RT-PCR
The results confirm differential expression between SCARKO and control testes and similarity of the expression patterns of the
studied genes. Expression values were corrected using luciferase mRNA as an external standard and are represented as the
mean  SEM of three independent experiments with triplicate measurements. Note that the expression levels of Eppin are much
higher than those of Pem, Drd4, and Gpd1.
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androgen target genes. Pem is a member of the Rhox
cluster of homeobox genes (33). Its regulation by an-
drogens in SC is well documented, and the androgen
response elements (AREs) mediating regulation by the
AR have been extensively characterized (34). Eppin is
a member of a highly conserved family of protease
inhibitors expressed in the testis and epididymis. The
presence of an ARE in the promoter region and immu-
noexpression in SC from d 12 onward have been
interpreted as indirect evidence of androgen regula-
tion (35). Finally, for a subset of nine of the genes
strongly down-regulated in SCARKO testes (Pem, Ep-
pin, Galgt1, Drd4, Tsx, Gpd1, Tubb3, PCI, and
Tpd52l1), we could demonstrate by quantitative RT-
PCR that treatment with the antiandrogen flutamide
for 5 d significantly decreased expression on d 12.
Whether all of these genes are directly or indirectly
regulated by androgens remains to be investigated.
Similarly, the exact cell(s) expressing the identified
genes remains to be identified. Quantitative RT-PCR
measurements after enzymatic separation of tubular
and interstitial tissue, however, suggest that the stud-
ied subset of nine genes is expressed predominantly
in the tubular compartment.
Other experimental paradigms have been used to
identify androgen-regulated genes in the testis. It is
striking that apart from Pem, the differentially ex-
pressed genes detected in the present study show
little overlap with androgen-regulated genes identified
in two other studies recently performed in hypogo-
nadal (hpg) and neonatal mice (36, 37). There may be
several explanations for this apparent discrepancy.
The SCARKO model may be expected to identify spe-
cifically genes whose expression depends on AR ac-
tion in SC, whereas in the other models, effects in-
duced by androgen administration may be mediated
not only by SC, but also by other AR-positive testicular
cells, such as peritubular myoid and Leydig cells.
Moreover, in both the hpg model and the neonatal
mouse studies, gene expression was studied early
(4–24 h) after androgen administration. In our experi-
mental setup, gene expression was studied on d 10.
Because AR expression in SC is observed from d 3–5,
it is conceivable that some of the observed effects are
Fig. 6. Expression Pattern of Genes Related to Tubular Remodeling and Junction Dynamics: Eppin, PCI, Tissue-Type Plasmin-
ogen Activator (tPA), Tubulin 3 (Tubb3), Actinin 3 (Actn3), Scinderin (Scin), Procollagen Type IV 6 (Col4a6), Thrombospondin
1 (Thbs1), Brevican (Bcan), Claudin 11 (Cldn11), Embigin (Emb), and Desmocollin (Dsc2)
Relative signal intensities were calculated as explained in Fig. 2.
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indirect and do not necessarily imply direct interaction
of the activated AR with an ARE in the relevant gene.
Finally, in the SCARKO model we are looking at the
effects of physiological amounts of endogenous an-
drogens, whereas in the other models high amounts of
exogenous androgens are administered. The absence
of FSH could be an additional factor affecting the
results in the hpg model.
The physiological relevance of the genes identified
by use of the SCARKO model is underscored by the
finding that three of the genes found to be markedly
down-regulated in SCARKOs (Galgt1, Eppin, and PCI)
have already been shown to be essential for normal
spermatogenesis and fertility. Eppin is a serine pro-
tease inhibitor discussed above. Immunization of male
monkeys against Eppin results in reversible contra-
ception, but the mechanism underlying this effect re-
mains to be defined (38). Gene inactivation of 1,4-N-
acetylgalactosaminyltransferase (Galgt1) or PCI
results in severe disruption of spermatogenesis.
Galgt1 encodes an enzyme involved in the formation
of complex gangliosides, and the infertility of
Galgt1/ mice may be related to a disturbance in the
production of a specific class of fucosylated glyco-
sphingolipids that are apparently essential for sper-
matogenesis (39, 40). PCI encodes a serine-type pro-
tease inhibitor, and spermatogenic failure in PCI/
mice has been related to disruption of the blood-testis
barrier (41).
To search for genes with a particular relevance to
the onset of spermatogenesis and the presence or
absence of AR activation in SC we also studied gene
expression in SCARKO and control testes between d
8 and 20 using microarray techniques and cluster
analysis. Cluster analysis of the subset of genes
known to be differentially expressed on d 10 revealed
three clusters that may be particularly relevant. Two of
these (clusters 3 and 4) identified subgroups of genes
displaying higher expression levels in mice with an
active AR in SC, but showing a different pattern of
change with time. Interestingly, these two clusters en-
compassed 71% of the genes down-regulated more
than 2-fold in SCARKOs. Cluster 5 encompassed 42%
of the genes identified as strongly up-regulated in
SCARKOs. Pem, which can be considered a lead gene
in the search for androgen-regulated genes in SC, was
found in cluster 4. A more detailed analysis of cluster
4, using hierarchical clustering, revealed that several
of the genes showing the highest up-regulation on d
10 (Eppin, Drd4, and Gpd1) clustered in the immediate
vicinity of Pem. Quantitative RT-PCR confirmed that
the expression of these genes strongly depended on
activation of the AR in SC and that their expression
pattern mimicked that of Pem. Eppin has been dis-
cussed above, and the present data are the first to
show directly that androgen action in SC enhances its
expression in the testis. We can only speculate about
the roles of Drd4 and Gpd1 in the testis. Drd4 encodes
a G protein-coupled receptor that is strongly ex-
pressed in the testis, but no testicular phenotype was
reported in mice lacking Drd4 (42, 43). Gpd1 encodes
a reduced nicotinamide adenine dinucleotide-depen-
dent enzyme involved in glycerol synthesis. Gpd1 is
ubiquitously expressed, but its promoter appears to
be highly methylated, specifically in sperm (44). Addi-
tional research will be required to clarify the roles and the
relationship of these genes to androgen action in SC.
There is increasing evidence that the interplay be-
tween proteases and protease inhibitors plays an im-
portant role in the restructuring of testicular tubules at
the onset of spermatogenesis and in the assembly and
functional dynamics of tight and adhesion junctions
between SC and germ cells (45, 46). Our data seem to
support this contention and provide preliminary evi-
dence that the AR in SC may play a more prominent
role in the control of these processes than previously
suspected. Both protease inhibitors and cell adhesion
molecules were overrepresented in the genes differ-
entially expressed in SCARKO and control testes.
Moreover, the time study showed that not only pro-
tease inhibitors and cell adhesion molecules, but also
cytoskeletal and extracellular matrix elements,
showed divergent expression patterns at the onset of
spermatogenesis.
In conclusion, the present study has identified a
subset of genes that are differentially expressed in d
10 testes with or without an active AR in SC. Some of
the identified genes have previously been shown to be
relevant for spermatogenesis or to be controlled by
androgens. Of particular interest is the finding that
some genes that may be related to tubular remodeling
and junction dynamics are affected by androgen ac-
tion in SC. Moreover, three genes with an expression
pattern strongly resembling that of the lead gene,
Pem, have been identified. These findings provide a
basis for additional dissection of the molecular mech-
anisms by which androgen action in SC affects
spermatogenesis.
MATERIALS AND METHODS
Tissue Sampling and RNA Extraction
To obtain SCARKO animals, female mice (129/Swiss) het-
erozygous for the floxed AR allele (ARflox/) (21) were mated
to male mice (C57BL/6) homozygous for the AMH-Cre trans-
gene (24). These AMH-Cre transgene animals were also used
as a control for SCARKO animals. All animals were treated
according to the National Institutes of Health Guide for the
Care and Use of Laboratory Animals, and all experiments
were approved by the local ethical committee. Whole testes
were obtained from animals at different ages depending on
the experiment. Immediately after removal, testis samples
were snap-frozen and stored in liquid nitrogen. Before RNA
extraction, testis samples were weighed and homogenized in
a Dounce homogenizer (Kontes Co., Vineland, NJ). Thereaf-
ter, RNA was isolated with the RNeasy Kit (Qiagen, Chats-
worth, CA) according to the manufacturer’s instructions, en-
compassing an on-column deoxyribonuclease I (DNase I)
treatment of the RNA. For quantitative RT-PCR analyses, 5
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ng luciferase mRNA (Promega Corp., Madison, WI) were
added to each testis sample before RNA preparation as an
external standard (47).
Immunohistochemistry
Standard procedures were used for hematoxylin and eosin
staining. A rabbit polyclonal antibody (N20) raised against a
peptide within the N-terminal domain of the human AR (sc-
816, Santa Cruz Biotechnology, Inc., Santa Cruz, CA) was
used at a 1:500 dilution. Rabbit anti-Dazl antibody was a gift
from Dr. H. J. Cooke (Medical Research Council Human
Genetics Unit, Edinburgh, UK) and was used at a 1:1000
dilution. Testes from d 10 control and SCARKO males were
removed, weighed, fixed in Bouin’s fluid for 4–6 h, and trans-
ferred into 70% (vol/vol) ethanol before processing into par-
affin wax using standard methods. Immunohistochemistry
was performed on dewaxed 5-m sections in conjunction
with heat-induced antigen retrieval for 5 min in 0.01 M citrate
buffer (pH 6.0; Sigma-Aldrich Corp., Dorset, UK) using a
pressure cooker. A swine antirabbit biotinylated second an-
tibody (E0353, DakoCytomation, Cambridge, UK) was used,
and details of the immunohistochemistry protocol were re-
ported previously (21).
To enable comparative evaluation of the immunostaining,
sections of tissues from control and knockout animals were
processed in parallel on at least three occasions to ensure
reproducibility of results; on each occasion, tissue sections
from four to six animals in each group were run. To ensure
direct comparability of staining intensities, one section each
from control and SCARKO mouse was mounted on the same
slide for the immunostaining procedure.
Microarray Target Synthesis and Processing
The quality of all testis RNA samples was monitored by
measuring the 260/280 and 260/230 nm ratios with a Nano-
Drop spectrophotometer (NanoDrop Technologies, Cen-
treville, DE) and by means of the Agilent 2100 BioAnalyzer
(Agilent, Palo Alto, CA). Only RNA showing no signs of deg-
radation or impurities (260/280 and 260/230 nm ratios, 1.8)
was considered suitable for microarray analysis.
Before target synthesis, RNA extracts from one testis of
three control or three SCARKO littermates were pooled, cre-
ating paired control and SCARKO samples optimally ad-
justed for potential variation between litters. Five micrograms
of polyadenylated RNA from each pool was reverse tran-
scribed into double-stranded DNA with a polydeoxythymi-
dine-T7 primer using SuperScript II RT, ribonuclease H, and
DNA polymerase I (Invitrogen Life Technologies, Inc., Carls-
bad, CA). From this double-stranded DNA, biotin-labeled
target aRNA was generated in a T7 in vitro transcription
reaction using the Affymetrix IVT Labeling Kit (Affymetrix,
High Wycombe, UK). After purification (GeneChip Sample
Cleanup Module, Affymetrix), yield (30–120 g) and purity
(260/280 and 260/230 nm ratios, 1.8) of the labeled ampli-
fied RNA were analyzed, 20 g quality-controlled amplified
RNA was fragmented by alkaline hydrolysis and resuspended
with control spikes in 300 l hybridization buffer (Eukaryotic
Hybridization Control Kit, Affymetrix). Of this probe solution,
200 l was used for hybridization in a rotisserie oven at 45 C.
The mouse expression array 430a 2.0 from Affymetrix was
used in all hybridizations. This array contains 22,690 tran-
scripts from Mus musculus, each represented by 11 probe
pairs. Each pair consists of a perfect match and a mismatch
(with a single base point mutation) 25-mer oligonucleotide
probe.
After hybridization, gene chips were washed and stained in
the GeneChip Fluidics Workstation 400 (Affymetrix) using the
EukGE-WS2v4 protocol and subsequently scanned with the
GeneChip Scanner 3000 (Affymetrix). Image analysis was
performed by use of Affymetrix GeneChip operating
software.
Microarray Data Analysis
A first experiment was set up to identify differentially ex-
pressed genes in the testis of 10-d-old control vs. SCARKO
mice. To this end, five control and five SCARKO samples
were compared. The data were considered paired because
the samples consisted two-by-two of testicular RNA from
littermate mice (see microarray target synthesis and process-
ing section). In an initial phase, results were analyzed using
Affymetrix Microarray Suite (MAS) 5.0 software. The amount
of transcripts in a sample that scored present, absent, or
marginally detectable was assessed. MAS 5.0 software was
also used to generate expression ratios after comparison of
a control dataset with its littermate SCARKO dataset. For
additional statistical analysis, all data were first normalized
using the robust multiarray analysis algorithm (RMA) (48, 49)
as implemented in the BioConductor packages (www.bio-
conductor.org) (50). Three statistical approaches, all part of
the BioConductor software, were used to identify differen-
tially expressed genes in testis of control vs. SCARKO mice:
1) significance analysis for microarrays (51), 2) a paired t test
controlling the false discovery rate using the Benjamini and
Hochberg correction (52), and 3) the moderated t test as
described in linear models for microarray data (53) also en-
compassing the Benjamini and Hochberg correction. A
threshold was set for each test, generating three lists of
differentially expressed transcripts (significance analysis for
microarrays: false discovery rate, P  0.05; paired t test and
Benjamini-Hochberg correction, P  0.05; linear models for
microarray data and Benjamini-Hochberg correction, P 
0.05). A cross-section of these lists was obtained in Access
(Microsoft Corp., Redmond, WA), yielding a summary of tran-
scripts that were depicted as differentially expressed in a
statistically significant way by all three tests. This list, which
contained 848 transcripts, was used for further analysis. On-
to-Express software (http://vortex.cs.wayne.edu/Projects.
html#Onto-Express) (25) was used to check for statistical
overrepresentation of certain molecular or biological func-
tions among the differentially expressed transcripts.
In a second experiment, we tried to identify typical expres-
sion patterns during initiation of spermatogenesis for the list
of differentially expressed transcripts generated. Hence,
gene expression was assessed in one control and one litter-
mate SCARKO sample at five different ages (d 8, 10, 12, 16,
and 20). After a first data analysis using MAS 5.0 software, as
described above, data were again RMA normalized for addi-
tional statistical analysis. An adaptive quality-based cluster-
ing using a heuristic iterative two-step algorithm (54), as
implemented in the INCLUSive package of web-based tools
(www.esat.kuleuven.ac.be/dna/BioI/Software.html), was
used in the search for expression patterns shared by genes
that were differentially expressed in d 10 animals. This
method is similar to k-means clustering, but has two advan-
tages. First, no prior choice of the number of clusters is
required, and second, not every gene is forced into a cluster.
Only significantly coexpressed genes are retained in a cluster
after derivation of its optimal radius. One of the resulting
clusters was further studied by calculating and visualizing
pairwise Euclidian distances between centered profiles using
hierarchical clustering as implemented in Expression Profiler
(http://ep.ebi.ac.uk) (26). Functional analysis of the clusters
was performed based on Onto-Express statistics.
In Vivo Treatment with Androgens and Antiandrogens
Seven-day-old C57BL/6@Rj mice (Janvier, Le Genest-St-
Isle, France) were treated for 3 or 5 d with TP (50 g/
animald), Flut (50 g/animald), or vehicle only. TP and Flut
were purchased from Fluka Chemie AG (Buchs, Switzerland)
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and Sigma-Aldrich Corp. Stock solutions were made in eth-
anol and then further diluted in arachis oil for injection. In all
conditions a volume of 50 l containing 10% ethanol was
injected sc. Treatment groups consisted of five animals. Mice
were killed on d 10 or 12, and testes were removed and
additionally processed for quantitative RT-PCR as described
above.
Enzymatic Separation of Interstitial and Tubular
Fractions
Interstitial and tubular fractions were prepared through enzy-
matic digestions essentially as described previously (55).
Twenty testes, derived from 10-d-old C57BL/6@Rj mice
(Janvier) were decapsulated and digested for 10 min with
trypsin (0.67 mg/ml) and DNase (6.7 g/ml) in a shaking water
bath (120 oscillations/min) at 32 C. The action of trypsin was
stopped by the addition of 2 mg/ml soybean trypsin inhibitor.
After sedimentation of the tubular fragments, the supernatant
was collected as the interstitial fraction, and the sedimented
tubular fragments were treated for an additional 5 min at 32
C with collagenase (0.67 mg/ml), hyaluronidase (0.67 mg/ml),
and DNase (10 g/ml). The remaining tubular fragments were
treated once more with hyaluronidase (0.67 mg/ml) and
DNase (10 g/ml) for about 15 min in a shaking water bath
(120 oscillations/min) to remove the remaining peritubular
cells. The resulting tubular fraction as well as the above-
generated interstitial fraction were centrifuged, snap-frozen
in liquid nitrogen, and stored at80 C until RNA preparation.
RNA was isolated using the Qiagen RNeasy kit with an on-
column DNase I treatment as described above.
Quantitative RT-PCR
cDNAwas synthesized using SuperScript II reverse transcrip-
tase and random hexamer primers (Invitrogen Life Technol-
ogies, Inc.). Primer sequences for Eppin, Galgt1, Drd4, Tsx,
Gpd1, Tubb3, PCI, Tpd52l1, and SCP3 are described in Table
1. Pem primer and probe sequences and 17-hydroxylase
(P450c17) primer sequences were described previously (21,
31). For quantification of gene expression, the ABI PRISM
7700 sequence detector PCR detection system (Applied Bio-
systems, Foster City, CA) was used with a two-step quanti-
tative RT-PCR protocol. Components for real-time PCR,
apart from primers and probes (Eurogentec, Sar-Tilman, Bel-
gium) and SYBR Green (Sigma-Aldrich Corp.), were obtained
from Applied Biosystems. For Eppin, Galgt1, Drd4, Tsx,
Gpd1, Tubb3, PCI, Tpd52l1, SCP3, and P450c17, each 25-l
real-time PCR contained 1	 buffer A, 5 mM MgCl2, 400 M
deoxy-NTPs, 200 nM of each primer, 0.4	 SYBR Green, and
0.025 U/l AmpliTaq Gold enzyme. The uniqueness of the
amplified band was checked by PAGE. For Pem, no SYBR
Green was used; instead, 100 nM of each primer and 400 nM
probe were added to the reaction. The quantity of measured
mRNA was expressed relative to the external luciferase
mRNA standard added before RNA preparation or to the 18S
rRNA present in the same sample. All samples and standard
curves were run in triplicate.
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